The changing landscape of hepatocellular carcinoma: Etiology, genetics, and therapy

American Journal of Pathology

Volumn 184, Issue 3, 2014, Pages 574-583

  Knudsen, Erik S ^a,b   Gopal, Purva ^a   Singal, Amit G ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

CARCINOMA, HEPATOCELLULAR; GENETIC VARIATION; GENETICS; HUMAN; LIVER NEOPLASMS; PATHOLOGY; PROGNOSIS;

BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; GENETIC VARIATION; HUMANS; LIVER NEOPLASMS; PROGNOSIS;

EID: 84894166118     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2013.10.028     Document Type: Review

References (102)

1. H.B. El-Serag, and K.L. Rudolph Hepatocellular carcinoma: epidemiology and molecular carcinogenesis Gastroenterology 132 2007 2557 2576 (Pubitemid 46890874)
2. H.B. El-Serag Epidemiology of viral hepatitis and hepatocellular carcinoma Gastroenterology 142 2012 1264 1273.e1
3. R. Beasley Hepatitis B virus. The major etiology of hepatocellular carcinoma Cancer 61 1988 1942 1956
4. M.W. Yu, H.C. Chang, Y.F. Liaw, S.M. Lin, S.D. Lee, C.J. Liu, P.J. Chen, T.J. Hsiao, P.H. Lee, and C.J. Chen Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives J Natl Cancer Inst 92 2000 1159 1164
5. M.C. Kew, and P. Macerollo Effect of age on the etiologic role of the hepatitis B virus in hepatocellular carcinoma in blacks Gastroenterology 94 1988 439 442 (Pubitemid 18054782)
6. G.S. Qian, R.K. Ross, M.C. Yu, J.M. Yuan, Y.T. Gao, B.E. Henderson, G.N. Wogan, and J.D. Groopman A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China Cancer Epidemiol Biomarkers Prev 3 1994 3 10 (Pubitemid 24172514)
7. H.B. El-Serag Hepatocellular carcinoma: recent trends in the United States Gastroenterology 127 2004 S27 S34 (Pubitemid 39423367)
8. F. Donato, P. Boffetta, and M. Puoti A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma Int J Cancer 75 1998 347 354 (Pubitemid 28100034)
9. G. Fattovich, G. Giustina, F. Degos, F. Tremolada, G. Diodati, P. Almasio, F. Nevens, A. Solinas, D. Mura, J.T. Brouwer, H. Thomas, C. Njapoum, C. Casarin, P. Bonetti, P. Fuschi, J. Basho, A. Tocco, A. Bhalla, R. Galassini, F. Noventa, S.W. Schalm, and G. Realdi Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients Gastroenterology 112 1997 463 472 (Pubitemid 27078833)
10. C.A. Sun, D.M. Wu, C.C. Lin, S.N. Lu, S.L. You, L.Y. Wang, M.H. Wu, and C.J. Chen Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan Am J Epidemiol 157 2003 674 682
11. H.O. Adami, A.W. Hsing, J.K. McLaughlin, D. Trichopoulos, D. Hacker, A. Ekbom, and I. Persson Alcoholism and liver cirrhosis in the etiology of primary liver cancer Int J Cancer 51 1992 898 902
12. M.M. Hassan, L.Y. Hwang, C.J. Hatten, M. Swaim, D. Li, J.L. Abbruzzese, P. Beasley, and Y.Z. Patt Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus Hepatology 36 2002 1206 1213 (Pubitemid 35253437)
13. B.Q. Starley, C.J. Calcagno, and S.A. Harrison Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection Hepatology 51 2010 1820 1832
14. D.L. White, F. Kanwal, and H.B. El-Serag Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review Clin Gastroenterol Hepatol 10 2012 1342 1359.e2
15. H. Tajiri, H. Tanaka, S. Brooks, and T. Takano Reduction of hepatocellular carcinoma in childhood after introduction of selective vaccination against hepatitis B virus for infants born to HBV carrier mothers Cancer Causes Control 22 2011 523 527
16. Y. Tanaka, K. Hanada, M. Mizokami, A.E. Yeo, J.W. Shih, T. Gojobori, and H.J. Alter A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades Proc Natl Acad Sci U S A 99 2002 15584 15589 (Pubitemid 35403976)
17. T. Umemura, T. Ichijo, K. Yoshizawa, E. Tanaka, and K. Kiyosawa Epidemiology of hepatocellular carcinoma in Japan J Gastroenterol 44 Suppl 19 2009 102 107
18. S.F. Altekruse, K.A. McGlynn, and M.E. Reichman Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005 J Clin Oncol 27 2009 1485 1491
19. A.G. Singal, A. Mukherjee, B.J. Elmunzer, P.D.R. Higgins, A.S. Lok, J. Zhu, J.A. Marrero, and A.K. Waljee Machine learning algorithms outperform conventional regression models in predicting development of hepatocellular carcinoma Am J Gastroenterol 108 2013 1723 1730
20. M.F. Yuen, Y. Tanaka, D.Y. Fong, J. Fung, D.K. Wong, J.C. Yuen, D.Y. But, A.O. Chan, B.C. Wong, M. Mizokami, and C.L. Lai Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B J Hepatol 50 2009 80 88
21. N. Chalasani, A. Said, R. Ness, H. Hoen, and L. Lumeng Screening for hepatocellular carcinoma in patients with cirrhosis in the United States: results of a national survey Am J Gastroenterol 94 1999 2224 2229 (Pubitemid 29374558)
22. A. Singal, M.L. Volk, A. Waljee, R. Salgia, P. Higgins, M.A. Rogers, and J.A. Marrero Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis Aliment Pharmacol Ther 30 2009 37 47
23. J. Bruix, and M. Sherman Management of hepatocellular carcinoma: an update Hepatology 53 2010 1 35
24. E. Lee, S. Edward, A.G. Singal, M.S. Lavieri, and M. Volk Improving screening for hepatocellular carcinoma by incorporating data on levels of alpha-fetoprotein, over time Clin Gastroenterol Hepatol 11 2013 437 440
25. J.A. Marrero, and H.B. El-Serag Alpha-fetoprotein should be included in the hepatocellular carcinoma surveillance guidelines of the American Association for the Study of Liver Diseases Hepatology 53 2011 1060 1061
26. A.G. Singal, H.S. Conjeevaram, M.L. Volk, S. Fu, R.J. Fontana, F. Askari, G.L. Su, A.S. Lok, and J.A. Marrero Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis Cancer Epidemiol Biomarkers Prev 21 2012 793 799
27. P. Gopal, A.C. Yopp, A.K. Waljee, J. Chiang, M. Nehra, P. Kandunoori, and A.G. Singal Factors that affect accuracy of alpha-fetoprotein test in detection of hepatocellular carcinoma in patients with cirrhosis Clin Gastroenterol Hepatol 2013 10.1016/j.cgh.2013.09.053 [Epub ahead of print]
28. Y. Sato, K. Nakata, Y. Kato, M. Shima, N. Ishii, T. Koji, K. Taketa, Y. Endo, and S. Nagataki Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein N Engl J Med 328 1993 1802 1806 (Pubitemid 23174710)
29. J.A. Marrero, Z. Feng, Y. Wang, M.H. Nguyen, A.S. Befeler, L.R. Roberts, K.R. Reddy, D. Harnois, J.M. Llovet, D. Normolle, J. Dalhgren, D. Chia, A.S. Lok, P.D. Wagner, S. Srivastava, and M. Schwartz Alpha-fetoprotein, Des-gamma Carboxyprothrombin, and Lectin-Bound Alpha-fetoprotein in Early Hepatocellular Carcinoma AFP, DCP, and AFP-L3 in Hepatocellular carcinoma Gastroenterology 137 2009 110 118
30. M. Capurro, I.R. Wanless, M. Sherman, G. Deboer, W. Shi, E. Miyoshi, and J. Filmus Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma Gastroenterology 125 2003 89 97 (Pubitemid 36799110)
31. J.M. Llovet, Y. Chen, E. Wurmbach, S. Roayaie, M.I. Fiel, M. Schwartz, S.N. Thung, G. Khitrov, W. Zhang, A. Villanueva, C. Battiston, V. Mazzaferro, J. Bruix, S. Waxman, and S.L. Friedman A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis Gastroenterology 131 2006 1758 1767 (Pubitemid 46001394)
32. J.A. Marrero, P.R. Romano, O. Nikolaeva, L. Steel, A. Mehta, C.J. Fimmel, M.A. Comunale, A. D'Amelio, A.S. Lok, and T.M. Block GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma J Hepatol 43 2005 1007 1012 (Pubitemid 41627986)
33. S. Shang, A. Plymoth, S. Ge, Z. Feng, H.R. Rosen, S. Sangrajrang, P. Hainaut, J.A. Marrero, and L. Beretta Identification of osteopontin as a novel marker for early hepatocellular carcinoma Hepatology 55 2012 483 490
34. L. Beneduce, F. Castaldi, M. Marino, S. Quarta, M. Ruvoletto, L. Benvegnu, F. Calabrese, A. Gatta, P. Pontisso, and G. Fassina Squamous cell carcinoma antigen-immunoglobulin M complexes as novel biomarkers for hepatocellular carcinoma Cancer 103 2005 2558 2565 (Pubitemid 40800535)
35. H. Yamagami, M. Moriyama, N. Tanaka, and Y. Arakawa Detection of serum and intrahepatic human hepatocyte growth factor in patients with type C liver diseases Intervirology 44 2001 36 42 (Pubitemid 32172942)
36. G. Mazziotti, F. Sorvillo, F. Morisco, A. Carbone, M. Rotondi, G. Stornaiuolo, D.F. Precone, M. Cioffi, G.B. Gaeta, N. Caporaso, and C. Carella Serum insulin-like growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a prospective study Cancer 95 2002 2539 2545 (Pubitemid 35424040)
37. N. Chignard, and L. Beretta Proteomics for hepatocellular carcinoma marker discovery Gastroenterology 127 2004 S120 S125 (Pubitemid 39423379)
38. J. Alexander, M. Torbenson, T.T. Wu, and M.M. Yeh Non-alcoholic fatty liver disease contributes to hepatocarcinogenesis in non-cirrhotic liver: a clinical and pathological study J Gastroenterol Hepatol 28 2013 848 854
39. M. Salomao, W.M. Yu, R.S. Brown Jr., J.C. Emond, and J.H. Lefkowitch Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH Am J Surg Pathol 34 2010 1630 1636
40. M. Salomao, H. Remotti, R. Vaughan, A.B. Siegel, J.H. Lefkowitch, and R.K. Moreira The steatohepatitic variant of hepatocellular carcinoma and its association with underlying steatohepatitis Hum Pathol 43 2012 737 746
41. D. Jain, N.C. Nayak, V. Kumaran, and S. Saigal Steatohepatitic hepatocellular carcinoma, a morphologic indicator of associated metabolic risk factors: a study from India Arch Pathol Lab Med 137 2013 961 966
42. S.K. Reddy, J.L. Steel, H.W. Chen, D.J. DeMateo, J. Cardinal, J. Behari, A. Humar, J.W. Marsh, D.A. Geller, and A. Tsung Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease Hepatology 55 2012 1809 1819
43. J.A. Marrero, R.J. Fontana, A. Barrat, F. Askari, H.S. Conjeevaram, G.L. Su, and A.S. Lok Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort Hepatology 41 2005 707 716 (Pubitemid 40462931)
44. U. Cillo, A. Vitale, F. Grigoletto, F. Farinati, A. Brolese, G. Zanus, D. Neri, P. Boccagni, N. Srsen, F. D'Amico, F.A. Ciarleglio, A. Bridda, and D.F. D'Amico Prospective validation of the Barcelona Clinic Liver Cancer staging system J Hepatol 44 2006 723 731
45. P.A. Farazi, and R.A. DePinho Hepatocellular carcinoma pathogenesis: from genes to environment Nat Rev Cancer 6 2006 674 687 (Pubitemid 44286000)
46. M.A. Buendia Genetics of hepatocellular carcinoma Semin Cancer Biol 10 2000 185 200
47. P. Bioulac-Sage, P. Laurent-Puig, C. Balabaud, and J. Zucman-Rossi Genetic alterations in hepatocellular adenomas Hepatology 37 2003 480 author reply -1
48. C. Guichard, G. Amaddeo, S. Imbeaud, Y. Ladeiro, L. Pelletier, I.B. Maad, J. Calderaro, P. Bioulac-Sage, M. Letexier, F. Degos, B. Clement, C. Balabaud, E. Chevet, A. Laurent, G. Couchy, E. Letouze, F. Calvo, and J. Zucman-Rossi Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma Nat Genet 44 2012 694 698
49. J. Huang, Q. Deng, Q. Wang, K.Y. Li, J.H. Dai, N. Li, Z.D. Zhu, B. Zhou, X.Y. Liu, R.F. Liu, Q.L. Fei, H. Chen, B. Cai, B. Zhou, H.S. Xiao, L.X. Qin, and Z.G. Han Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma Nat Genet 44 2012 1117 1121
50. A. Fujimoto, Y. Totoki, T. Abe, K.A. Boroevich, F. Hosoda, and H.H. Nguyen et al. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators Nat Genet 44 2012 760 764
51. Z. Kan, H. Zheng, X. Liu, S. Li, T.D. Barber, and Z. Gong et al. Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma Genome Res 23 2013 1422 1433
52. H. Nakagawa, and T. Shibata Comprehensive genome sequencing of the liver cancer genome Cancer Lett 340 2013 234 240
53. M. Imielinski, A.H. Berger, P.S. Hammerman, B. Hernandez, T.J. Pugh, and E. Hodis et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing Cell 150 2012 1107 1120
54. M. Krauthammer, Y. Kong, B.H. Ha, P. Evans, A. Bacchiocchi, J.P. McCusker, E. Cheng, M.J. Davis, G. Goh, M. Choi, S. Ariyan, D. Narayan, K. Dutton-Regester, A. Capatana, E.C. Holman, M. Bosenberg, M. Sznol, H.M. Kluger, D.E. Brash, D.F. Stern, M.A. Materin, R.S. Lo, S. Mane, S. Ma, K.K. Kidd, N.K. Hayward, R.P. Lifton, J. Schlessinger, T.J. Boggon, and R. Halaban Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma Nat Genet 44 2012 1006 1014
55. S.I. Nikolaev, D. Rimoldi, C. Iseli, A. Valsesia, D. Robyr, C. Gehrig, K. Harshman, M. Guipponi, O. Bukach, V. Zoete, O. Michielin, K. Muehlethaler, D. Speiser, J.S. Beckmann, I. Xenarios, T.D. Halazonetis, C.V. Jongeneel, B.J. Stevenson, and S.E. Antonarakis Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma Nat Genet 44 2012 133 139
56. N. Harada, H. Oshima, M. Katoh, Y. Tamai, M. Oshima, and M.M. Taketo Hepatocarcinogenesis in mice with beta-catenin and Ha-ras gene mutations Cancer Res 64 2004 48 54 (Pubitemid 38114081)
57. A.K. McClendon, J.L. Dean, A. Ertel, Z. Fu, D.B. Rivadeneira, C.A. Reed, R.J. Bourgo, A. Witkiewicz, S. Addya, C.N. Mayhew, H.L. Grimes, P. Fortina, and E.S. Knudsen RB and p53 cooperate to prevent liver tumorigenesis in response to tissue damage Gastroenterology 141 2011 1439 1450
58. B.C. Lewis, D.S. Klimstra, N.D. Socci, S. Xu, J.A. Koutcher, and H.E. Varmus The absence of p53 promotes metastasis in a novel somatic mouse model for hepatocellular carcinoma Mol Cell Biol 25 2005 1228 1237 (Pubitemid 40204903)
59. C. Kadoch, D.C. Hargreaves, C. Hodges, L. Elias, L. Ho, J. Ranish, and G.R. Crabtree Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy Nat Genet 45 2013 592 601
60. J.S. Lee, and S.S. Thorgeirsson Functional and genomic implications of global gene expression profiles in cell lines from human hepatocellular cancer Hepatology 35 2002 1134 1143 (Pubitemid 34454010)
61. J.S. Lee, I.S. Chu, J. Heo, D.F. Calvisi, Z. Sun, T. Roskams, A. Durnez, A.J. Demetris, and S.S. Thorgeirsson Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling Hepatology 40 2004 667 676 (Pubitemid 39265589)
62. J.S. Lee, and S.S. Thorgeirsson Genome-scale profiling of gene expression in hepatocellular carcinoma: classification, survival prediction, and identification of therapeutic targets Gastroenterology 127 2004 S51 S55 (Pubitemid 39423369)
63. C.N. Mayhew, S.L. Carter, S.R. Fox, C.R. Sexton, C.A. Reed, S.V. Srinivasan, X. Liu, K. Wikenheiser-Brokamp, G.P. Boivin, J.S. Lee, B.J. Aronow, S.S. Thorgeirsson, and E.S. Knudsen RB loss abrogates cell cycle control and genome integrity to promote liver tumorigenesis Gastroenterology 133 2007 976 984 (Pubitemid 47374137)
64. S.L. Carter, A.C. Eklund, I.S. Kohane, L.N. Harris, and Z. Szallasi A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers Nat Genet 38 2006 1043 1048 (Pubitemid 44325930)
65. Y. Hoshida, S.M. Nijman, M. Kobayashi, J.A. Chan, J.P. Brunet, D.Y. Chiang, A. Villanueva, P. Newell, K. Ikeda, M. Hashimoto, G. Watanabe, S. Gabriel, S.L. Friedman, H. Kumada, J.M. Llovet, and T.R. Golub Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma Cancer Res 69 2009 7385 7392
66. A. Villanueva, Y. Hoshida, C. Battiston, V. Tovar, D. Sia, C. Alsinet, H. Cornella, A. Liberzon, M. Kobayashi, H. Kumada, S.N. Thung, J. Bruix, P. Newell, C. April, J.B. Fan, S. Roayaie, V. Mazzaferro, M.E. Schwartz, and J.M. Llovet Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma Gastroenterology 140 2011 1501 1512.e2
67. S. Boyault, D.S. Rickman, A. de Reynies, C. Balabaud, S. Rebouissou, E. Jeannot, A. Herault, J. Saric, J. Belghiti, D. Franco, P. Bioulac-Sage, P. Laurent-Puig, and J. Zucman-Rossi Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets Hepatology 45 2007 42 52 (Pubitemid 46144363)
68. C.M. Perou, T. Sorlie, M.B. Eisen, M. van de Rijn, S.S. Jeffrey, C.A. Rees, J.R. Pollack, D.T. Ross, H. Johnsen, L.A. Akslen, O. Fluge, A. Pergamenschikov, C. Williams, S.X. Zhu, P.E. Lonning, A.L. Borresen-Dale, P.O. Brown, and D. Botstein Molecular portraits of human breast tumours Nature 406 2000 747 752
69. Y. Hoshida, A. Villanueva, A. Sangiovanni, M. Sole, C. Hur, K.L. Andersson, R.T. Chung, J. Gould, K. Kojima, S. Gupta, B. Taylor, A. Crenshaw, S. Gabriel, B. Minguez, M. Iavarone, S.L. Friedman, M. Colombo, J.M. Llovet, and T.R. Golub Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis Gastroenterology 144 2013 1024 1030
70. J.C. Nault, A. De Reynies, A. Villanueva, J. Calderaro, S. Rebouissou, G. Couchy, T. Decaens, D. Franco, S. Imbeaud, F. Rousseau, D. Azoulay, J. Saric, J.F. Blanc, C. Balabaud, P. Bioulac-Sage, A. Laurent, P. Laurent-Puig, J.M. Llovet, and J. Zucman-Rossi A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection Gastroenterology 145 2013 176 187
71. B. Minguez, Y. Hoshida, A. Villanueva, S. Toffanin, L. Cabellos, S. Thung, J. Mandeli, D. Sia, C. April, J.B. Fan, A. Lachenmayer, R. Savic, S. Roayaie, V. Mazzaferro, J. Bruix, M. Schwartz, S.L. Friedman, and J.M. Llovet Gene-expression signature of vascular invasion in hepatocellular carcinoma J Hepatol 55 2011 1325 1331
72. S.M. Kim, S.H. Leem, I.S. Chu, Y.Y. Park, S.C. Kim, S.B. Kim, E.S. Park, J.Y. Lim, J. Heo, Y.J. Kim, D.G. Kim, A. Kaseb, Y.N. Park, X.W. Wang, S.S. Thorgeirsson, and J.S. Lee Sixty-five gene-based risk score classifier predicts overall survival in hepatocellular carcinoma Hepatology 55 2012 1443 1452
73. J. Bruix, and J.M. Llovet Major achievements in hepatocellular carcinoma Lancet 373 2009 614 616
74. S.K. Olsen, R.S. Brown, and A.B. Siegel Hepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapies Therap Adv Gastroenterol 3 2010 55 66
75. A. Forner, J.M. Llovet, and J. Bruix Hepatocellular carcinoma Lancet 379 2012 1245 1255
76. C.R. de Lope, S. Tremosini, A. Forner, M. Reig, and J. Bruix Management of HCC J Hepatol 56 Suppl 1 2012 S75 S87
77. L. Rossi, F. Zoratto, A. Papa, F. Iodice, M. Minozzi, L. Frati, and S. Tomao Current approach in the treatment of hepatocellular carcinoma World J Gastrointest Oncol 2 2010 348 359
78. C.W. Chua, and S.P. Choo Targeted therapy in hepatocellular carcinoma Int J Hepatol 2011 2011 348297
79. M.A. Worns, A. Weinmann, M. Schuchmann, and P.R. Galle Systemic therapies in hepatocellular carcinoma Dig Dis 27 2009 175 188
80. J.M. Llovet, and J. Bruix Molecular targeted therapies in hepatocellular carcinoma Hepatology 48 2008 1312 1327
81. J.M. Llovet, and J. Bruix Novel advancements in the management of hepatocellular carcinoma in 2008 J Hepatol 48 Suppl 1 2008 S20 S37
82. R.S. Finn Development of molecularly targeted therapies in hepatocellular carcinoma: where do we go now? Clin Cancer Res 16 2010 390 397
83. J.M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, J.F. Blanc, A.C. de Oliveira, A. Santoro, J.L. Raoul, A. Forner, M. Schwartz, C. Porta, S. Zeuzem, L. Bolondi, T.F. Greten, P.R. Galle, J.F. Seitz, I. Borbath, D. Haussinger, T. Giannaris, M. Shan, M. Moscovici, D. Voliotis, J. Bruix, and S.I.S. Group Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
84. M.B. Thomas, D. Jaffe, M.M. Choti, J. Belghiti, S. Curley, Y. Fong, G. Gores, R. Kerlan, P. Merle, B. O'Neil, R. Poon, L. Schwartz, J. Tepper, F. Yao, D. Haller, M. Mooney, and A. Venook Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting J Clin Oncol 28 2010 3994 4005
85. J.M. Llovet, A.M. Di Bisceglie, J. Bruix, B.S. Kramer, R. Lencioni, A.X. Zhu, M. Sherman, M. Schwartz, M. Lotze, J. Talwalkar, and G.J. Gores Design and endpoints of clinical trials in hepatocellular carcinoma J Natl Cancer Inst 100 2008 698 711
86. J.M. Llovet, and J. Bruix Testing molecular therapies in hepatocellular carcinoma: the need for randomized phase II trials J Clin Oncol 27 2009 833 835
87. R.S. Finn, Y.K. Kang, M. Mulcahy, B.N. Polite, H.Y. Lim, I. Walters, C. Baudelet, D. Manekas, and J.W. Park Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma Clin Cancer Res 18 2012 2090 2098
88. J.W. Park, R.S. Finn, J.S. Kim, M. Karwal, R.K. Li, F. Ismail, M. Thomas, R. Harris, C. Baudelet, I. Walters, and J.L. Raoul Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma Clin Cancer Res 17 2011 1973 1983
89. M.B. Thomas, R. Chadha, K. Glover, X. Wang, J. Morris, T. Brown, A. Rashid, J. Dancey, and J.L. Abbruzzese Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma Cancer 110 2007 1059 1067 (Pubitemid 47312872)
90. M.B. Thomas, J.S. Morris, R. Chadha, M. Iwasaki, H. Kaur, E. Lin, A. Kaseb, K. Glover, M. Davila, and J. Abbruzzese Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma J Clin Oncol 27 2009 843 850
91. A. Santoro, L. Rimassa, I. Borbath, B. Daniele, S. Salvagni, J.L. Van Laethem, H. Van Vlierberghe, J. Trojan, F.T. Kolligs, A. Weiss, S. Miles, A. Gasbarrini, M. Lencioni, L. Cicalese, M. Sherman, C. Gridelli, P. Buggisch, G. Gerken, R.M. Schmid, C. Boni, N. Personeni, Z. Hassoun, G. Abbadessa, B. Schwartz, R. Von Roemeling, M.E. Lamar, Y. Chen, and C. Porta Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study Lancet Oncol 14 2013 55 63
92. J. Trojan, and S. Zeuzem Tivantinib in hepatocellular carcinoma Expert Opin Investig Drugs 22 2013 141 147
93. M.H. Chang, C.J. Chen, M.S. Lai, H.M. Hsu, T.C. Wu, M.S. Kong, D.C. Liang, W.Y. Shau, and D.S. Chen Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group N Engl J Med 336 1997 1855 1859
94. A.G. Singal, M.L. Volk, D. Jensen, A.M. Di Bisceglie, and P.S. Schoenfeld A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus Clin Gastroenterol Hepatol 8 2010 280 288 288.e1
95. A.S. Lok, D.F. Gardiner, E. Lawitz, C. Martorell, G.T. Everson, R. Ghalib, R. Reindollar, V. Rustgi, F. McPhee, M. Wind-Rotolo, A. Persson, K. Zhu, D.I. Dimitrova, T. Eley, T. Guo, D.M. Grasela, and C. Pasquinelli Preliminary study of two antiviral agents for hepatitis C genotype 1 N Engl J Med 366 2012 216 224
96. F. Bravi, C. Bosetti, A. Tavani, and C. La Vecchia Coffee drinking and hepatocellular carcinoma: an update Hepatology 50 2009 1317 1318
97. S. Singh, P.P. Singh, A.G. Singh, M.H. Murad, and W. Sanchez Statins Are Associated With a Reduced Risk of Hepatocellular Cancer: A Systematic Review and Meta-analysis Gastroenterology 144 2013 323 332
98. J.A. Davila, L. Henderson, J.R. Kramer, F. Kanwal, P.A. Richardson, Z. Duan, and H.B. El-Serag Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States Ann Intern Med 154 2011 85 93
99. A.G. Singal, A. Yopp, C. SS, M. Packer, W.M. Lee, and J.A. Tiro Utilization of hepatocellular carcinoma surveillance among American patients: a systematic review J Gen Intern Med 27 2012 861 867
100. A.G. Singal, A. Yopp, S. Gupta, C.S. Skinner, E.A. Halm, E. Okolo, M. Nehra, W.M. Lee, J.A. Marrero, and J.A. Tiro Failure rates in the hepatocellular carcinoma surveillance process Cancer Prevent Res 5 2012 1124 1130
101. A.G. Singal, J.A. Tiro, and S. Gupta Improving hepatocellular carcinoma screening: applying lessons from colorectal cancer screening Clin Gastroenterol Hepatol 11 2013 472 477
102. A.G. Singal, M. Nehra, B. Adams-Huet, A.C. Yopp, J.A. Tiro, J.A. Marrero, A.S. Lok, and W.M. Lee Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail? Am J Gastroenterol 108 2013 425 432